发现功能化的1ββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ
Princess Simeon1, Ramu Venkatesan1, Xiaoyu Hao1
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68106, United States.
Journal of medicinal chemistry
|September 1, 2025
概括
研究人员开发了一种新型化合物,用于治疗神经状脂肪瘤 (NCL),这是一个罕见的儿童神经退行性疾病. 这些化合物有望减少患者细胞中的疾病特征, 提供潜在的治疗益处.
科学领域:
- 神经科学
- 遗传学
- 药理学
背景情况:
- 神经状脂肪 (NCLs) 是致命的儿童神经退行性疾病.
- 这种CLN3亚型是由CLN3基因突变引起的,导致脂素积累和线粒体功能障碍.
- 目前对NCL的治疗选择有限,病理生理学尚不清楚.
研究的目的:
- 合成和描述神经保护化合物flupirtine和retigabine的新型双循环类似物.
- 开发可以避免与原始药物相关的有毒代谢中间体的化合物.
- 在患者CLN3细胞模型中评估这些新化合物的疗效.
主要方法:
- 新型1H-[d]imidazole衍生物的合成和表征.
- 使用来自患者的CLN3诱导多能干细胞 (iPSC) 模型.
- 评估了神经保护作用和CLN3表型特征的减少.
主要成果:
- 新的双循环类似物,特别是1H-[d]imidazoles,已经成功合成.
- 化合物9b和38b在CLN3 iPSC模型中显示出显著的保护作用.
- 化合物减少了CLN3病理的主要表型特征,并表现出有利的药理动力学.
结论:
- 新的胺化合物提供了对CLN3病理的增强神经保护.
- 这些化合物减轻了原始药物的毒性代谢负担.
- 选择的化合物显示为一种罕见的神经退行性疾病的CLN3的治疗药物.
相关概念视频
01:22iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
01:21EPS and iPS Cells in Disease Research
2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K